Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU

NCT02998996 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

162

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza, Human

Interventions

BIOLOGICAL: 15 µg HA/strain and 1% Endocine™
BIOLOGICAL: 15 µg HA/strain and 2% Endocine™
BIOLOGICAL: 15 µg HA/strain
BIOLOGICAL: intramuscular comparator
BIOLOGICAL: intranasal comparator
BIOLOGICAL: Placebo, Saline

Sponsor

Eurocine Vaccines AB